Contact information
Type
Public
Primary contact
Ms Marie Hyslop
ORCID ID
Contact details
The Institute of Cancer Research
15 Cotswold Road
Belmont
Sutton
SM2 5NG
United Kingdom
+44 20 8722 4305
CTC-STOP-icrctsu@icr.ac.uk
Additional identifiers
EudraCT number
2015-001361-27
ClinicalTrials.gov number
NCT03327662
Protocol/serial number
34057
Study information
Scientific title
CTC-STOP: Utilising Circulating Tumour Cell (CTC) Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer
Acronym
CTC-STOP
Study hypothesis
The aim of this study is to determine whether a blood test which detects the number of circulating tumour cells (CTC’s) could provide an earlier indicator for doctors to decide when to stop one chemotherapy treatment (docetaxel) and start another (cabazitaxel).
Ethics approval
London - Surrey Borders Research Ethics Committee, 21/09/2016, ref: 16/LO/1502
Study design
Randomised; Interventional; Design type: Treatment, Process of Care, Drug, Device, Active Monitoring
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Diagnostic
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Prostate cancer
Intervention
Patients with a Circulating Tumour Cell (CTC) count of over (and including) 5 cells at screening will be randomised 1:1 to either the control group (standard of care) or intervention group (CTC guided treatment). The trial has a two-stage entry process of registration and randomisation. Randomisation only occurs following confirmation of CTCs over (and including) 5 cells per 7.5 mL of blood and all other eligibility criteria. The Randomisation procedure will be performed via computer programme, centrally by the Institute of Cancer Research Clinical Trials Statistics Unit (ICR-CTSU). All patients regardless of group will commence first line chemotherapy with docetaxel 75mg/m2 three-weekly and will receive a minimum of 3 cycles of treatment before any recommendation to discontinue first-line docetaxel.
Control Group (standard of care): Participants will receive first line docetaxel until disease progression according to the treating doctor or completion of 10 cycles of treatment. Patients and treating doctors in the control group will not be disclosed to the results of CTC determinations (apart from the screening CTC value).
Intervention Group (CTC-guided treatment group): Participants will receive first line docetaxel until progression by CTCs, and/or disease progression according to the treating doctor or completion of 10 cycles of treatment. CTC results will be available to the treating doctor to guide decision-making. A progressing CTC count on Day 1 will require confirmation with a second CTC count performed on Day 15 of that cycle (except when the Cycle 2 Day 1 CTC count shows progression; needs to be subsequently confirmed by CTC progression on Cycle 3 Day 1 CTC count).If a patient is found to have two successive CTC determinations showing progression by CTCs, the doctor will receive a recommendation from the trial Chief Investigator to discontinue docetaxel on the following cycle.
The reasons of the treating doctor to discontinue docetaxel will be reported in both groups. Patients who discontinue first line docetaxel according to the criteria for each group will be switched to second line chemotherapy with cabazitaxel. After progression on cabazitaxel or completion of 10 cycles, patients will be followed up every three months until the end of study.
Intervention type
Other
Phase
Phase III
Drug names
Primary outcome measure
Overall survival is measured by the time from randomisation date to the date of death or last follow-up of the patient. After on-treatment visits, patient status and survival of patient are assessed every 12 weeks (patients’ notes and/or interview) until death or loss to follow of the patient, or end of study. The time point of interest for the main analysis is the estimate of overall survival at 24 months.
Secondary outcome measures
1. Proportion of patients in the intervention group that undergo a chemotherapy switch guided by CTC results. This is assessed once 200 patients are recruited and have completed at least 24 weeks of docetaxel treatment
2. Number of cycles of docetaxel administered per patient (with a maximum of 10 cycles allowed) reviewed at 24 months post last patient first visit.
3. Safety is assessed by the rate of adverse events with first and second line chemotherapy; these are assessed at baseline, CxD1 for both treatments, Pre-cabazitaxel follow up visits (if patient receives 10 cycles of docetaxel), EOT and First Off Treatment Follow Up Visit
4. Quality of life is assessed using the FACT-P and EQ-5D questionnaires at baseline, CxD1 for both treatments, Pre-cabazitaxel follow up visits (if patient receives 10 cycles of docetaxel), EOT and First Off Treatment Follow Up Visit
5. Pain (progression and response) is measured by the Brief Pain Inventory Form and the Analgesic use at CxD1 for both treatments
6. Progression Free Survival is measured by the time from randomisation until disease progression, death or end of follow-up, whatever occurs first. Disease progression is defined per the PCWG2 criteria and includes: PSA progression, radiographic progression and clinical progression
6.1. PSA progression is assessed at baseline, CxD1 for both treatments, Pre-cabazitaxel follow up visits (if patient receives 10 cycles of docetaxel), EOT and First Off Treatment Follow Up Visit
6.2. Radiographic progression is assessed by CT/whole Body MRI and bone scans performed at baseline and as per clinical practice, every 2-3 months
6.3. Clinical progression is assessed by pain, analgesic use, patient reported symptoms and clinical assessment and is assessed at baseline and CxD1 for both treatments, Pre-cabazitaxel follow up visits (if patient receives 10 cycles of docetaxel), EOT and First Off Treatment Follow Up Visit
7. Radiographic Progression Free Survival is measured by the time from randomisation until radiographic progression, death or end of follow-up, whatever occurs first
8. Time to First Symptomatic Skeletal Related Event is measured form the date of randomisation to the date of the first documented symptomatic skeletal related event, defined by first occurrence of use of external beam radiation therapy, new symptomatic pathological fractures, spinal cord compression or tumour-related orthopaedic interventions. These events are assessed by imaging assessments at baseline and as per clinical practice, every 2-3 months; adverse events and clinical notes at baseline, CxD1 for both treatments, Pre-cabazitaxel follow up visits (if patient receives 10 cycles of docetaxel), EOT and First Off Treatment Follow Up Visit.
9. Time to CTC progression is measured from randomisation and assessed by CTC blood tests at CxD1 on docetaxel.
10. % Change from baseline values of CTC and PSA during first and second line therapy is assessed by CTC blood test and PSA blood test at CxD1 for both treatments
11. Proportion of patients with a stable CTC count by 12-weeks is assessed by CTC blood tests taken at C3D1 (or earlier if first line treatment discontinued)
12. Health economic assessments assessed by Health Economic Questionnaire Forms collected at CxD1 for both treatments (except C1D1 docetaxel), Pre-cabazitaxel follow up visits (if patient receives 10 cycles of docetaxel), EOT and First Off Treatment Follow Up Visit
Overall trial start date
01/07/2014
Overall trial end date
31/01/2022
Reason abandoned (if study stopped)
Participant recruitment issue
Eligibility
Participant inclusion criteria
1. Written informed consent
2. Male patients over and including 18 years on the date of consent
3. Histologically confirmed diagnosis of adenocarcinoma of the prostate with availability of archival tumour tissue for molecular analyses (small cell prostate cancer is an exclusion); if no histological diagnosis has ever been acquired a fresh tumour biopsy confirming the presence of CRPC must be pursued
4. Metastatic castration-resistant disease with only bone metastases, confirmed by bone scan (within 4 weeks) or CT/ whole body MRI (within 6 weeks), of starting this trial (Cycle 1 Day 1). Patients with local recurrence, and bone metastases with an associated soft tissue component, will be allowed into the trial. Pelvic lymphadenopathy <2cm in size is not an exclusion.
5. Systemic chemotherapy indicated for disease progression, defined as:
5.1. Bone Scan Progression: Two or more documented new bone lesions over previous 6 months
AND/OR
5.2. Increasing serum PSA level: Two consecutive increases in PSA levels documented over a previous reference value obtained at least one week apart are required. If the third PSA value is less than the second, an additional fourth test to confirm the rising PSA is required
6. Baseline laboratory values as stated below:
6.1. Creatinine ≤1.5 x upper limit of normal (ULN)
6.2. Bilirubin ≤1.0 x ULN
6.3. SGOT (AST) and SGPT (ALT) ≤2.5 x ULN
6.4. Castrate serum testosterone level (<50 ng/dL-or-<1.7 nmol/L)
6.5. ANC ≥1.5 x 109cells/L
6.6. Platelet count ≥100 x 109/L
6.7. PSA ≥ 5ng/mL
7. CTC levels ≥ 5 cells / 7.5 mL
8. Prior treatment with abiraterone and/or enzalutamide, discontinued due to disease progression
9. Patient willing to continue primary androgen suppression with gonadotropin-releasing hormone (GnRH) analogues (either agonists or antagonists) throughout the study, unless treated with bilateral orchiectomy
10. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2
11. At least 3 weeks should have elapsed since stopping any investigational agent at the time of randomisation. More than 4 weeks since completion of radiotherapy, other than when a single palliative fraction is administered when only a two week interval is required before trial treatment commencement.
12. Patient has recovered from any therapy-related toxicity to ≤ grade 2, (except alopecia, anaemia and any signs or symptoms of androgen deprivation therapy)
13. Patients willing to comply with the study protocol and follow-up schedule; these conditions should be discussed with the patient before registration in the trial
14. Patients must be surgically sterile or must agree to use effective contraception during the period of the therapy and for 12 months after the last dose of study treatment
Participant type
Patient
Age group
Adult
Gender
Male
Target number of participants
Planned Sample Size: 1178; UK Sample Size: 833
Participant exclusion criteria
1. Received any prior cytotoxic chemotherapy as treatment for castration-resistant prostate cancer. Patients that have received chemotherapy for hormone-sensitive metastatic prostate cancer will be allowed onto the trial, if the patient merits retreatment with docetaxel and at least 12 months has elapsed since the patient has completed that previous docetaxel therapy.
2. Measurable soft tissue or lymph node metastases or any metastatic disease outside the bone that is RECIST measurable will be an exclusion (unless it is pelvic nodal disease <2cm in size). Bone metastases with associated soft tissue components will also not be an exclusion.
3. Received any cycling, intermittent or continuous hormonal treatment 28 days prior to randomisation with the exception of the continuous LHRH analogues
4. History of or current documented brain metastasis or carcinomatous meningitis, treated or untreated. Brain imaging for asymptomatic patients is not required.
5. Current symptomatic cord compression requiring surgery or radiation therapy (once the patient is successfully treated the patient will be considered eligible for the study)
6. Active second malignancy (except non-melanoma skin or superficial bladder cancer) defined as requiring anticancer therapy or within the previous two years
7. Serious medical conditions such as heart failure, myocardial infarction, pulmonary thromboembolism within 12 months; stroke or treatment of a major active infection within 3 months of randomisation, as well as any significant medical illness that in the opinion of the Investigator would preclude protocol therapy
8. Planned concomitant participation in another clinical trial of an experimental agent, vaccine, or device. Concomitant participation in observational studies is acceptable.
9. Hypersensitivity to the active substance, to any of its excipients (including polysorbate 80) or to other taxanes
10. Concomitant vaccination with yellow fever vaccine
11. Concomitant use of medicinal products that are strong CYP3A inducers
Recruitment start date
11/01/2017
Recruitment end date
31/01/2020
Locations
Countries of recruitment
United Kingdom
Trial participating centre
Royal Marsden Hospital
Downs Road
Sutton
SM2 5PT
United Kingdom
Sponsor information
Organisation
The Institute of Cancer Research
Sponsor details
15 Cotswold Road
Belmont
Sutton
SM2 5NG
United Kingdom
+44 20 8722 4154
barbara.pittam@icr.ac.uk
Sponsor type
Hospital/treatment centre
Website
Funders
Funder type
Charity
Funder name
Prostate Cancer UK
Alternative name(s)
Funding Body Type
private sector organisation
Funding Body Subtype
Other non-profit organizations
Location
United Kingdom
Results and Publications
Publication and dissemination plan
The main trial results will be published in a peer-reviewed journal, on behalf of all collaborators. The first planned publication will focus on the planned feasibility analysis to evaluate the feasibility of utilizing CTCs to inform early discontinuation of docetaxel and switch to cabazitaxel. This will occur after the first 200 patients have been randomised and followed for at least 24 weeks or until docetaxel discontinuation (whichever occurs first).
IPD sharing statement:
The current data sharing plans for the current study are unknown and will be made available at a later date.
Intention to publish date
31/01/2023
Participant level data
To be made available at a later date
Basic results (scientific)
Publication list